IDC: Enterprise HIEs will grab larger share of info exchange market

The health information exchange (HIE) infrastructure will change dramatically over the next two years with enterprise HIEs potentially reaping the benefits, according to a report from health market researcher IDC Health Insights.

The report evaluated 14 vendors supplying HIE applications for enterprise, regional and statewide health information organizations and is intended to assist providers in determining the HIE technology and vendor best suited to an organization's existing IT environment and business needs.

IDC reported that it anticipates that enterprise HIEs serving integrated delivery networks, health or hospital systems will be the fastest-growing market segment of HIE organizations.

Unlike regional health information organizations (RHIOs) and statewide or national HIEs, enterprise HIEs can establish a sustainable business model and are not as encumbered by organizational and data governance issues, according to the Framingham, Mass.-based firm.

According to IDC, the evaluation was based on two assessments: "Fit to Market Needs" and "Ownership Confidence." "Fit to Market Needs" included 10 criteria to evaluate the strength of a product in terms of feature/functionality, interoperability, architecture, quality of service and support and cost. "Ownership Confidence" included five criteria to evaluate the soundness of a technology supplier's strategy, financials, commitment to an industry and customer satisfaction.

“We can expect dramatic changes in the next 12 to 18 months as HIE technologies become a commodity and dominant players acquire their way into a crowded market currently made up of many small, privately held vendors," wrote report author Lynne Dunbrack, program director of IDC Health Insights.

The evaluated venders included Axolotl, Browsersoft/Open HRE, Carefx, dbMotion, eClinicalWorks, InterSystems, MEDecision, Medicity, Medseek, Microsoft, Oracle, Orion Health, PatientKeeper and RelayHealth.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.